Marc Posel Email

VP, Corporate Controller . ReCode Therapeutics

Current Roles

Employees:
155
Revenue:
$24M
About
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. The Company's diverse pipeline includes lead programs for cystic fibrosis (CF) caused by nonsense mutations, and primary ciliary dyskinesia (PCD). ReCode has developed a non-viral delivery therapeutic platform that enables it to precisely deliver its medicines safely and effectively. The Company is leveraging its lipid nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. For more information, visit www.recodetx.com or contact us at info@recodetx.com.
ReCode Therapeutics Address
1140 O’Brien Drive
Menlo Park, TX
United States
ReCode Therapeutics Email

Past Companies

ReCode TherapeuticsVP, Corporate Controller
Agena BioscienceCorporate Controller
Ansun Biopharma, Inc.Director of Finance

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.